BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects
- Conditions
- Renal Insufficiency, ChronicAnemia
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT03351166
- Locations
- 🇯🇵
Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan
🇯🇵Asahikawa-Kosei General Hospital, Asahikawa, Hokkaido, Japan
🇯🇵Ishikari Hospital, Ishikari, Hokkaido, Japan
A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
- Conditions
- AnemiaRenal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 164
- Registration Number
- NCT03350347
- Locations
- 🇯🇵
Matsunami Health Promotion Clinic, Hashima-gun, Gifu, Japan
🇯🇵Mazda Hospital of Mazda Motor Corporation, Aki-gun, Hiroshima, Japan
🇯🇵Higashihiroshima Medical Center, Higashihiroshima, Hiroshima, Japan
A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects
- Conditions
- AnemiaRenal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 162
- Registration Number
- NCT03350321
- Locations
- 🇯🇵
Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan
🇯🇵St.Mary's Hospital, Kurume, Fukuoka, Japan
🇯🇵Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 287
- Registration Number
- NCT03349684
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Sun Yat-Sen Memorial Hosp. Sun Yat-Sen Univ., Guangzhou, Guangdong, China
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: Regorafenib(Stivarga, BAY73-4506)
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 58
- Registration Number
- NCT03347292
- Locations
- 🇺🇸
USC Norris Hospital and Clinics, Los Angeles, California, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇩🇪Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany
Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT03342859
- Locations
- 🇬🇧
Edinburgh Royal Infirmary/ NHS Lothian, Edinburgh, United Kingdom
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT03334838
- Locations
- 🇦🇷
FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina
Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment
- Conditions
- Osteoarthritis
- Interventions
- Drug: Theraflex, BAY 874017
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1102
- Registration Number
- NCT03330288
- Locations
- 🇷🇺
Sci-Res Institute of Rheumatology n.a. V.A. Nasonova of RAMS, Moscow, Russian Federation
🇷🇺Many locations, Multiple Locations, Russian Federation
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Bayer
- Registration Number
- NCT03325127
Treatment Satisfaction With Ra-223 in Japan
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 85
- Registration Number
- NCT03315260
- Locations
- 🇯🇵
Many Locations, Multiple Locations, Japan